Passage Bio
Manufacturing · Pennsylvania, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2005 Market St Fl 39, Philadelphia, Penn...Phone Number
(267) 866-0311Website
www.passagebio.comRevenue
$12.7 MillionStock Symbol
PASGIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
3
1
1
1
1
About Passage Bio
Founded in 2017, Passage Bio is a genetic medicines company based in Philadelphia, PA that is developing a portfolio of six life transforming AAV-delivered therapeutics for the treatment of rare monogenic central nervous system diseases.Explore more
Passage Bio Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Passage Bio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Passage Bio had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Passage Bio, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Passage Bio
Check if Passage Bio has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Passage Bio recently announced quarterly report
Funding: Get notified immidiatlly once Passage Bio has new funding data
Check out if Passage Bio is spiking on competitors!
Product Launch: Get notified when Passage Bio launches new products
Recommended Actions
Find VP level buyers at Passage Bio
Find 2 more new buyers
Compare Similar Companies to Passage Bio
Compare insights from companies similar to Passage Bio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Passage Bio is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Passage Bio is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Passage Bio.
Passage Bio financials insights
Gather financial insights about Passage Bio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Series A
$115.5M
Series B
$110M
2020
Stock Offering
$216M
Passage Bio Tech Stack
A closer look at the technologies used by Passage Bio
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
Financial Reporting, Clinical Operations
Person-Based
Events, Finance, Investor Relations
Project
Passage Bio is expecting to hold a pre-BLA meeting in the fourth quarter and submit a BLA in the first quarter of next year for its AMT-130 program.
Compliance, Pharmaceuticals, Clinical Operations
Project
Compliance, Pharmaceuticals, Artificial Intelligence, Clinical Operations
Passage Bio News & Media
Passage launches strategic review and 75% layoffs after gene therapy path blocked by FDA
The layoffs are part of a strategic review sparked by the FDA's refusal to allow Passage's gene therapy trial to be single-arm.Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates
PBFT02 administration resulted in improvements in two disease progression biomarkers, as compared to natural history, reducing brain atrophy and stabilizing plasma NfL levelsPassage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business Highlights
Enrolled first three FTD-GRN patients in Cohort 3 of ongoing upliFT-D studyPassage Bio to Participate in Upcoming Investor Conferences
PHILADELPHIA, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced management will participate in the following upcoming investor conferences:
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Passage Bio
Sign Up For FreeTo access detailed company insights
Founded in 2017, Passage Bio is a genetic medicines company based in Philadelphia, PA that is developing a portfolio of six life transforming AAV-delivered therapeutics for the treatment of rare monogenic central nervous system diseases.... Read More
